Lupin Pharmaceuticals has obtained FDA approval for Suprax (Cefixime) for oral suspension, 500 mg/5mL and anticipates initiating product shipment shortly.
Suprax oral suspension is indicated for otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections, uncomplicated gonorrhea (cervical/urethral) and pharyngitis/tonsillitis.
Lupin Group president Vinita Gupta said, "The new dosage form will add to our growing Suprax franchise and gives health care providers and patients a new formulation to treat the indicted infections."
At present, Suprax is available as 100mg/5ml and 200mg/5ml suspensions, 400mg tablets besides chewable tablets of 100 and 200mg strengths.
Source:
http://drugdiscovery.pharmaceutical-business-review.com/news/lupin-to-commence-shipment-of-suprax-oral-suspension-220213
